Licensed rights and other intangible assets

12 Months Ended

Dec. 31, 2022

Goodwill And Intangible Assets Disclosure [Abstract]

Licensed rights and other intangible assets

5. Licensed rights and other intangible assets

The following provides information about our license rights and other intangible assets, net (in thousands):

	As of December 31, 2022						As of December 31, 2021
	Gross						Gross
	Carrying		Accumulated				Carrying		Accumulated
	Amount		Amortization		Net		Amount		Amortization		Net
Intangible assets    subject to amortization:
Hormone therapy drug patents	$	6,225	$	1,598	$	4,627	$	5,834	$	1,042	$	4,792
Hormone therapy drug patents applied    and pending approval		1,995		—		1,995		2,020		—		2,020
Intangible assets    subject to amortization		8,220		1,598		6,622		7,854		1,042		6,812
Intangible assets not subject to amortization:
Trademarks/trade name rights		321		—		321		332		—		332
Intangible assets, net	$	8,541	$	1,598	$	6,943	$	8,186	$	1,042	$	7,144

We recorded, in continuing operations, amortization expense related to patents of $0.6 million for 2022 and $0.3 million for 2021.We recorded amortization expense related to the exclusive license rights agreement with Population Council of $3.0 million for 2022 and 2021, which was reclassified to discontinued operations after we completed transaction with Mayne Pharma in December 2022, which are excluded from the table above.  

Our intangible assets subject to amortization are expected to be amortized as follows (in thousands):

Year ending December 31,
2023	$	337
2024		439
2025		438
2026		438
2027		438
Thereafter		2,537
Total	$	4,627

We use a combination of qualitative and quantitative factors to assess licensed rights and intangible assets for impairment. As a result of performing these assessments, we determined that no impairment existed as of December 31, 2022 or 2021, therefore, no write downs were recorded to our licensed rights and other intangible assets.